This article summarized the latest R&D progress of Fluphenazine Decanoate, the Mechanism of Action for Fluphenazine Decanoate, and the drug target R&D trends for Fluphenazine Decanoate.

TransCode Therapeutics has reported positive findings with its primary treatment candidate, TTX-MC138, in mouse models with human glioblastoma multiforme tumors.

This article summarized the latest R&D progress of Hydrochlorothiazide/Lisinopril, the Mechanism of Action for Hydrochlorothiazide/Lisinopril, and the drug target R&D trends for Hydrochlorothiazide/Lisinopril.

RIPK1, also known as Receptor-interacting serine/threonine-protein kinase 1, is a multi-domain protein that includes an N-terminal kinase domain, intermediate domain, and a C-terminal death domain.

This article summarized the latest R&D progress of Isophane Insulin, the Mechanism of Action for Isophane Insulin, and the drug target R&D trends for Isophane Insulin.

NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.

This article summarized the latest R&D progress of Magnesium Salicylate, the Mechanism of Action for Magnesium Salicylate, and the drug target R&D trends for Magnesium Salicylate.

The Renin-Angiotensin System (RAS) is a crucial fluid-regulating system composed of a series of peptide hormones and corresponding enzymes.

This article summarized the latest R&D progress of Miglitol, the Mechanism of Action for Miglitol, and the drug target R&D trends for Miglitol.

Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

This article summarized the latest R&D progress of Nalidixic Acid, the Mechanism of Action for Nalidixic Acid, and the drug target R&D trends for Nalidixic Acid.

RANKL, or Receptor Activator of Nuclear Factor Kappa-B Ligand, is a crucial protein involved in the regulation of bone metabolism in the human body.